Group 1: Market Competition and Product Strategy - The company acknowledges 11 competitors for the Loxoprofen Sodium Gel Patch, including its subsidiary, and plans to actively respond to competition by leveraging its complete industrial chain to control costs and ensure product quality [2] - The company has established a comprehensive channel coverage system, particularly in the outpatient market, which has become a new growth engine, with plans to increase investment for greater market share [2] - The company aims to enhance its "Jiuyue" brand through first-mover advantages, channel advantages, and cost advantages to solidify its leading position in the transdermal drug delivery field [2] Group 2: Financial Performance and Projections - For 2025, the company expects a revenue growth of 10-20% year-on-year, with a similar increase in net profit excluding non-recurring items, subject to market conditions and other uncertainties [3] - The company emphasizes the importance of risk awareness among investors regarding its operational plans and sales forecasts [3] Group 3: Strategic Initiatives for Growth - To achieve its annual goals, the company will focus on promoting new products, enhancing market penetration through education and product positioning, and increasing efforts in the outpatient market [4] - The company plans to deepen its presence in chain pharmacies and community clinics to tap into the growth potential of the outpatient market [4] - Brand building will be accelerated to enhance the recognition of core brands like "Jiuyue," driving market share expansion [4] Group 4: Product Sales Characteristics - The company reports that its product sales do not exhibit significant seasonality or cyclicality [5] Group 5: Innovation and Development - The company is developing a Class 1 innovative drug, the Pepper Seven Pain Relief Gel Patch, and has entered into a technology transfer agreement for antibacterial and anti-inflammatory peptides to support innovative drug development [6] - The company is actively recruiting talent for innovative drug research and development to strengthen its future capabilities [6] Group 6: Market Outlook for Specific Products - The sales channels for the anti-inflammatory pain relief patch will primarily focus on OTC channels, with strategies to enhance sales through resource sharing and product matrix expansion [7] - The company holds an optimistic view on the market prospects for the anti-inflammatory pain relief patch, anticipating growth in the chronic pain patient population due to societal aging, which will further drive demand for transdermal products [7]

Group 1 - The company, Jiutian Pharmaceutical, announced on August 1 that it has repurchased a total of 6,180,800 shares through a special securities account via centralized bidding, which accounts for 1.24% of the company's current total share capital [1]

格隆汇8月1日丨九典制药(300705.SZ)公布，截至2025年7月31日，公司通过股份回购专用证券账户以集 中竞价交易方式累计回购股份6,180,800股，占公司目前总股本的1.24%，最高成交价为18.44元/股，最 低成交价为14.51元/股，成交总金额为1.00亿元(不含交易费用)。 ...

| 证券代码：300705 | 证券简称：九典制药 | | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | 公告编号：2025-054 | 湖南九典制药股份有限公司 关于回购公司股份的进展公告 本公司及董事会全体成员保证向本公司提供的信息内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于 2025 年 2 月 17 日召开 第四届董事会第九次会议，审议通过了《关于回购公司股份方案的议案》，同意 公司通过集中竞价交易方式以自有资金和股票回购专项贷款资金回购部分社会 公众股份，用于后期实施股权激励计划。本次回购的资金总额不低于人民币 10,000 万元且不超过人民币 15,000 万元，回购价格不超过人民币 24.98 元/股， 实施期限为自董事会审议通过回购股份方案之日起 12 个月内。具体内容详见公 司在巨潮资讯网披露的《回购股份报告书》（公告编号：2025-012）等相关公告。 后续公司将在回购期限内，结合市场情况适时推进股份回购工作，并根据相 关法律法规及时履行信息披露义务，敬请投资者注意投资风险。 ...

Core Viewpoint - The company, Jiutian Pharmaceutical, is actively engaged in the research, development, and sales of pharmaceutical products, with a focus on expanding its product offerings and market presence through innovation and internationalization efforts [1][8]. Group 1: Product Development and Market Strategy - Jiutian Pharmaceutical is currently in the information reporting phase for the 11th batch of centralized procurement for its drug, Loxoprofen Sodium Gel Patch, and cannot estimate the price reduction at this stage [2]. - The company has six external preparations already on the market and expects to gain approval for additional products, including Indomethacin Gel Patch and Flurbiprofen Gel Patch, by 2025, with further products anticipated in 2026 [3]. - The company has developed a new sales strategy for Ketoprofen Gel Patch, which was approved in 2023 and has entered the national medical insurance directory, focusing on increasing resources for the outpatient market and enhancing internal sales team assessments [5]. Group 2: International Expansion and Innovation - Jiutian Pharmaceutical has made progress in exporting its formulations, having developed 46 international clients, with successful exports to Ecuador and preparations for registration in Costa Rica [4]. - The company is also focusing on innovation, with a new product, Pepper Seven Pain Relief Gel Patch, classified as a Class 1 innovative drug, and has entered into a technology transfer agreement for antimicrobial peptides to enhance its drug development capabilities [6]. Group 3: Financial Performance and R&D Investment - In the first quarter of 2025, Jiutian Pharmaceutical reported a main revenue of 696 million yuan, a year-on-year increase of 17.79%, and a net profit of 126 million yuan, reflecting a slight increase of 0.08% [8]. - The company plans to invest 261 million yuan in R&D in 2024, which represents 8.91% of its operating income, and aims to maintain this investment ratio to ensure continuous output and enhance its competitive edge [7]. Group 4: Earnings Forecast - Recent earnings forecasts indicate that Jiutian Pharmaceutical's net profit is expected to reach approximately 677 million yuan in 2025, with projections of 775 million yuan in 2026 and further growth anticipated in 2027 [11].

Group 1 - Hunan Hongchen Pharmaceutical Co., Ltd. has been established with a registered capital of 120 million yuan [1] - The legal representative of the company is Zheng Xiahui, and the company is co-owned by Jiu Dian Pharmaceutical, Zheng Xiahui, and Xiao Kunyue [1] - The business scope includes drug production, drug retail, and various chemical product manufacturing and sales [1] Group 2 - The company is involved in both licensed and general projects, including drug import and export, and technology services [1] - The company is also engaged in ecological environment material manufacturing and sales, as well as non-residential real estate leasing [1] - The company operates under the approval of relevant departments for certain projects [1]

Group 1: Investor Relations Activity - The investor relations activity involved a meeting with representatives from Taikang Asset and China Post Securities, held on July 30, 2025 [2] - The meeting was led by the Deputy General Manager and Board Secretary, Zeng Lei, along with the Securities Affairs Representative, Gan Rong [2] Group 2: Product Development and Market Strategy - The company is currently in the information reporting stage for the collection of the eleventh batch of the drug Loxoprofen Sodium Gel Patch, with no specific price reduction estimates available yet [2] - The company has six external preparations already on the market and expects to gain approval for additional products, including Indomethacin Gel Patch and Flurbiprofen Gel Patch in 2025, and Ketoprofen Patch and others in 2026 [2][3] - The company has made progress in export development, with 46 clients engaged, including successful exports of Nitazoxanide Tablets to Ecuador and preparations for the registration of Ketoprofen Gel in Costa Rica [4] Group 3: Sales Expectations and Brand Strategy - The Ketoprofen Gel Patch was approved for market entry in 2023 and is included in the national medical insurance directory, with optimistic market prospects and a new sales strategy focusing on outpatient markets [5] - The company aims to strengthen its internal sales team assessments to enhance the "Jiu Yue" brand of patches [5] Group 4: Innovation and R&D Investment - The company is developing a Class 1 innovative drug, Pepper Seven Pain Relief Gel Patch, and has entered into a technology transfer agreement for antibacterial and anti-inflammatory peptides [6] - In 2024, the company plans to invest CNY 261 million in R&D, representing 8.91% of its revenue, with a commitment to maintain this investment ratio for sustained innovation and market competitiveness [7]

九典制药（300705.SZ）7月29日在投资者互动平台表示，您好！公司的全资子公司汇阳信息暂无人工智 能、算力等相关业务。 （文章来源：每日经济新闻） 每经AI快讯，有投资者在投资者互动平台提问：子公司汇阳信息能详细介绍下吗？有人工智能、算力 吗？ ...

Group 1 - The company, Jiutian Pharmaceutical, has responded to investor inquiries regarding its products for treating joint pain, which include Loxoprofen Sodium Gel Patches, Ketoprofen Gel Patches, Anti-inflammatory Pain Relief Plasters, and Ketoprofen Gel [1] - The company also offers antipyretic medications such as Loxoprofen Sodium Tablets and Loxoprofen Sodium Oral Solutions [1]

Group 1: Product Information - The price of Loxoprofen Sodium Gel Patch in local procurement is approximately [2] - The company believes that Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch complement each other in the market and do not compete directly [2] - Currently, the Loxoprofen Sodium Gel Patch is in the information submission phase for the 11th batch of centralized procurement [3] Group 2: R&D and Product Development - The company has six external preparations already on the market, including Loxoprofen Sodium Gel Patch and Ketoprofen Gel Patch [3] - Expected approvals in 2025 include Indomethacin Gel Patch and Flurbiprofen Gel Patch, while approvals in 2026 are anticipated for Ketoprofen Patch and others [3] Group 3: Marketing Strategy - The company focuses on continuous R&D investment to enrich its product matrix and leverage first-mover, scale, and cost advantages [3] Group 4: Financial Outlook - The company projects a revenue growth of 10-20% for 2025, with a similar expected increase in net profit [3] - There are risks associated with achieving these targets due to market conditions and industry policies, which may lead to uncertainties in forecasts [3]